An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
← catalyst calendarNCT07426757 · readout in 1,056 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
120estimated
Sites
19
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-01 | actual | When the study began enrolling |
| Primary completion | 2029-07-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-10 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Advanced Malignancies
- Advanced Cancer
Interventions
- Drug: PF-07994525
- Drug: Midazolam
Primary outcomes
what the primary-completion date above is the date OFType, incidence and severity of participants with adverse events (AEs)
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Type, incidence and severity of participants with laboratory abnormalities
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Number of participants with dose modifications
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
measured Baseline to end of DLT evaluation period
Part 1: Recommended Monotherapy Dose for Expansion (RDE)
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Part 2: Recommended Dose for future development
measured From the first day through 30-37 days after the last study treatment, up to approximately 2 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed